100388-13-4Relevant academic research and scientific papers
Preparation and medical use for tetrahydroisoquinoline compound and salt of tetrahydroisoquinoline compound
-
Paragraph 0273; 0274, (2018/07/30)
The invention discloses a novel tetrahydroisoquinoline compound as well as a preparation method, a pharmaceutical composition and use thereof and particularly discloses a compound represented by a general formula (I) (shown in the description), a pharmaceutically acceptable salt of the compound, a preparation process of the compound, a pharmaceutical composition containing the compound representedby the general formula (I) and application of the compound and the composition in the treatment of diseases relevant with type 2 diabetes mellitus, hyperlipidemia and fatty liver.
Design, synthesis, and biological activity of novel PPARγ ligands based on rosiglitazone and 15d-PGJ2
Usui, Shinya,Suzuki, Takayoshi,Hattori, Yoshifumi,Etoh, Kazuma,Fujieda, Hiroki,Nishizuka, Makoto,Imagawa, Masayoshi,Nakagawa, Hidehiko,Kohda, Kohfuku,Miyata, Naoki
, p. 1547 - 1551 (2007/10/03)
To develop novel PPARγ ligands, we synthesized thirteen 3-{4-(2-aminoethoxy)phenyl}propanoic acid derivatives, which are designed based on the structures of rosiglitazone and 15d-PGJ2. Among these compounds, compound 9 was found to be as potent as rosiglitazone in a binding assay and a preadipocyte differentiation test. Molecular modeling suggested that the nonyl group of 9 interacted with hydrophobic amino acid residues constructing the hydrophobic region of PPARγ protein where the alkyl chain of 15d-PGJ2 is expected to be located.
